Paraplegia News and Research

RSS

Paraplegia is an impairment in motor or sensory function of the lower extremities. It is usually the result of spinal cord injury or a congenital condition such as spina bifida which affects the neural elements of the spinal canal.

Role of hybrid Brain Computer Interface in people with paraplegia

"Brain Computer Interface" pursues the objective to extract information from human brain waves in order to provide persons suffering from severe disabilities with a communication system.

21 Feb 2011

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

11 Feb 2011

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Neuralstem, Inc. announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted it orphan drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS) with its human spinal cord derived neural stem cells (NSI-566RSC), currently in a Phase I safety study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

10 Feb 2011

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

After a spinal cord injury a number of factors impede the regeneration of nerve cells. Two of the most important of these factors are the destabilization of the cytoskeleton and the development of scar tissue.

29 Jan 2011

Neuralstem ends litigation with ReNeuron

Neuralstem, Inc. announced that it has reach a settlement with ReNeuron, Ltd. ending litigation between the parties.

28 Jan 2011

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

Engineers have developed a new type of microchip muscle stimulator implant that will enable people with paraplegia to exercise their paralysed leg muscles.

23 Nov 2010

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

18 Nov 2010

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

20 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Patients fitted with long-term bladder catheters often face a potentially serious complication caused by a Gram-negative bacteria Proteus mirabilis that can colonize the catheters.

16 Sep 2010

Study on spinal cord stem cells paves way for post stroke symptom treatment

Neuralstem, Inc. announced that its spinal cord stem cells survived in rat brains affected by stroke and differentiated predominantly into neurons. The transplanted animals showed significant improvement in some motor skill and strength measurements. The study entitled, "Intracerebral Implantation of Adherent Human Neural Stem Cells To Reverse Motor Deficits in Chronic Stroke Rats," was presented earlier today by senior study author, Dr. Shinn-Zong Lin, M.D., Ph.D., at the Stem Cells USA & Regenerative Medicine Conference

15 Sep 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Neuralstem, Inc. announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course. This patent describes methods of culturing and expanding neural stem cells.

19 Aug 2010

Benefits of drug L-methionine for neurogenic bladder disorders unclear

It is unclear whether patients with neurogenic bladder disorders benefit from the drug L-methionine. The only study currently available provides neither proof of benefit nor proof of harm. This is the result of a report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 12 July 2010.

20 Jul 2010

Medtronic launches educational campaign to promote awareness on spasticity

Medtronic, Inc. today announced the launch of an educational campaign, called Release Your Potential, that is designed to raise awareness of spasticity, a condition that makes it difficult to voluntarily relax muscles.

14 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Neuralstem, Inc. announced today that it has entered into definitive agreements to sell $10 million of units at $2.80 per unit in a registered-direct offering to institutional investors. The units consist of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years.

25 Jun 2010

New study data on distal aortic perfusion for thoracoabdominal aortic aneurysm repair

The vascular surgeons at Massachusetts General Hospital (MGH) in Boston have traditionally repaired thoracoabdominal aortic aneurysms (TAA) with a clamp and sew (CS) technique that includes neuro-protective adjuncts like epidural cooling and aggressive intercostal reconstruction (IC) to prevent spinal cord ischemia.

11 Jun 2010

Neuralstem updates progress of ongoing Phase I human clinical trial for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient.

25 May 2010